Balance Sheet Account Detail (Tables)

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Cash and Cash Equivalents and Marketable Securities

The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:

	Cost		Foreign Currency Translation			Gross Unrealized Gains		Estimated fair Value		Cash and equivalents		Marketable Securities
												Current
December 31, 2018
Equity securities* (see Note 3(h) and Note 10)	$	8,710	$	(2,168	)	$	39,880	$	46,422	$	—	$	46,422
Bank deposits	14,735		—			—		14,735		14,735		—
Money market funds	142,745		—			—		142,745		142,745		—
Bank certificates of deposits	86		—			—		86		—		86
Total cash and cash equivalents and marketable securities	$	166,276	$	(2,168	)	$	39,880	$	203,988	$	157,480	$	46,508
December 31, 2017
Bank deposits	$	10,965	$	—		$	—	$	10,965	$	10,965	$	—
Money market funds	216,358		—			—		216,358		216,358		—
Bank certificates of deposits	248		—			—		248		—		248
Total cash and cash equivalents and marketable securities	$	227,571	$	—		$	—	$	227,571	$	227,323	$	248

* Beginning January 1, 2018, under the new requirements of ASU 2016-01, Recognition and Measurement of Financial Assets and Liabilities, the unrealized (loss) gains on our CASI Pharmaceuticals, Inc. (NASDAQ: CASI) (“CASI”) equity securities are recognized as a (decrease) increase to “other income, net” on the Consolidated Statements of Operations (rather than through “other comprehensive (loss) income” on the Consolidated Statements of Comprehensive Loss). Our adoption of ASU 2016-01 on January 1, 2018, resulted in a $17.2 million cumulative-effect adjustment, net of income tax, recorded as a decrease to “accumulated other comprehensive (loss) income” and a decrease to “accumulated deficit” on the accompanying Consolidated Balance Sheets. Our recognized unrealized gain on these equity securities for the year ended December 31, 2018 was $10.5 million, as reported in “other income, net” on the accompanying Consolidated Statements of Operations.

Schedule of Property and Equipment Net of Accumulated Depreciation

“Property and equipment, net of accumulated depreciation” consists of the following:

	December 31,
	2018			2017
Computers hardware and software	$	3,079		$	2,994
Laboratory equipment	635			630
Office furniture	212			218
Leasehold improvements	2,957			2,938
Property and equipment, at cost	6,883			6,780
(Less): Accumulated depreciation	(6,498		)	(6,191		)
Property and equipment, net of accumulated depreciation	$	385		$	589

Components of Inventories

“Inventories” consists of the following:

	December 31,
	2018			2017
Raw materials	$	2,024		$	1,077
Work-in-process	2,209			2,551
Finished goods	1,193			5,187
(Less:) Non-current portion of inventories included within "other assets" *	(1,876		)	(3,100		)
Inventories	$	3,550		$	5,715

* The “non-current” portion of inventories is presented within "other assets" in the accompanying Consolidated Balance Sheets at December 31, 2018 and 2017, respectively. This value of $1.9 million at December 31, 2018 represents product that we expect to sell beyond December 31, 2019, and the value at December 31, 2017 represented product that we expected to sell beyond December 31, 2018.

Summary of Customers Representing 10% or More of Accounts Receivables

A summary of our customers that represent 10% or more of our accounts receivables as of December 31, 2018 and 2017, are as follows:

	December 31,
	2018				2017
AmerisourceBergen Corporation, and its affiliates	$	10,448	35.0	%	$	7,175	22.2	%
Cardinal Health, Inc. and its affiliates	8,228		27.5	%	9,514		29.5	%
McKesson Corporation and its affiliates	7,615		25.5	%	11,186		34.7	%
All other customers	3,582		12.0	%	4,385		13.6	%
Accounts receivable, net	$	29,873	100.0	%	$	32,260	100.0	%

Schedule of Prepaid Expenses and Other Assets

“Prepaid expenses and other assets” consists of the following:

	December 31,
	2018		2017
Other miscellaneous prepaid operating expenses	$	8,186	$	3,389
Prepaid insurance	782		645
Research and development supplies	611		1,883
Key employee life insurance – cash surrender value	—		4,150
Prepaid expenses and other assets	$	9,579	$	10,067

Schedule of Other Receivables

“Other receivables” consists of the following:

	December 31,
	2018		2017
CASI note - short term (Note 11)	$	1,525	$	—
Other miscellaneous receivables (including Medicaid rebate credits and royalty receivables)	1,189		1,152
Insurance receivable	206		53
Income tax receivable	643		665
Reimbursements due from development partners for incurred research and development expenses	135		263
Other receivables	$	3,698	$	2,133

Components of Intangible Assets Net of Accumulated Amortization

“Intangible assets, net of accumulated amortization” consists of the following:

			December 31, 2018
	Historical Cost		Accumulated Amortization			Foreign Currency Translation			Impairment			Net Amount		Full Amortization Period (months)	Remaining Amortization Period (months)
MARQIBO IPR&D (NHL and other novel indications)	$	17,600	$	—		$	—		$	—		$	17,600	n/a	n/a
EVOMELA distribution rights	7,700		(1,629		)	—			—			6,071		156	123
KHAPZORY distribution rights (1)	2,650		(379		)	—			—			2,271		14	12
BELEODAQ distribution rights	25,000		(8,438		)	—			—			16,562		160	106
MARQIBO distribution rights	26,900		(21,501		)	—			—			5,399		81	18
FOLOTYN distribution rights	118,400		(67,187		)	—			—			51,213		152	47
ZEVALIN distribution rights – U.S.	41,900		(41,031		)	—			—			869		123	3
ZEVALIN distribution rights – Ex-U.S.	23,490		(18,071		)	(3,409		)	—			2,010		96	15
FUSILEV distribution rights (2)	16,778		(9,618		)	—			(7,160		)	—		56	0
FOLOTYN out-license (3)	27,900		(17,278		)	—			(1,023		)	9,599		110	43
Total intangible assets (4)	$	308,318	$	(185,132	)	$	(3,409	)	$	(8,183	)	$	111,594

			December 31, 2017
	Historical Cost		Accumulated Amortization			Foreign Currency Translation			Impairment			Net Amount
MARQIBO IPR&D (NHL and other novel indications)	$	17,600	$	—		$	—		$	—		$	17,600
EVOMELA distribution rights	7,700		(1,037		)	—			—			6,663
BELEODAQ distribution rights	25,000		(6,563		)	—			—			18,437
MARQIBO distribution rights	26,900		(17,182		)	—			—			9,718
FOLOTYN distribution rights	118,400		(54,111		)	—			—			64,289
ZEVALIN distribution rights – U.S.	41,900		(37,557		)	—			—			4,343
ZEVALIN distribution rights – Ex-U.S.	23,490		(17,232		)	(2,471		)	—			3,787
FUSILEV distribution rights (2)	16,778		(9,618		)	—			(7,160		)	—
FOLOTYN out-license (3)	27,900		(14,555		)	—			(1,023		)	12,322
Total intangible assets (4)	$	305,668	$	(157,855	)	$	(2,471	)	$	(8,183	)	$	137,159

(1) In November 2018, we made a $2.7 million payment to Medac related to the FDA approval of KHAPZORY for its commercial sale. This amount was capitalized to "KHAPZORY distribution rights" during the fourth quarter of 2018 and will be amortized through December 31, 2019 (see Note 17(b)(xvi)).

(2) On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition for the remaining net book value of FUSILEV distribution rights. Effective December 2018, FUSILEV has been discontinued and we are no longer selling this product. We have since transitioned to marketing KHAPZORY for the same indications as FUSILEV.

(3) On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million resulted from this amendment.

(4)     See Note 1(a) for a discussion of the Acrotech Transaction, relating to our pending sale of these intangible assets.

Estimated Intangible Asset Amortization Expense

Estimated intangible asset amortization expense for the five succeeding years and thereafter is as follows (without consideration of the completion of the Acrotech Transaction - see Note 1(a)):

Years Ending December 31,
2019	$	27,333
2020	19,748
2021	18,266
2022	15,882
2023	2,467
2024 and thereafter	10,298
	$	93,994

Schedule of Goodwill

“Goodwill” consists of the following:

	December 31,
	2018			2017
Acquisition of Talon (MARQIBO rights)	$	10,526		$	10,526
Acquisition of ZEVALIN Ex-U.S. distribution rights	2,525			2,525
Acquisition of Allos (FOLOTYN rights)	5,346			5,346
Foreign currency exchange translation effects	(336		)	(235		)
Goodwill	$	18,061		$	18,162

Summary of Other Assets

“Other assets” consists of the following:

	December 31,
	2018		2017
Key employee life insurance – cash surrender value	$	6,274	$	10,737
Inventories - non-current portion	1,876		3,100
Research & development supplies and other	1,340		231
Income tax receivable*	668		668
Equity securities (see Note 11)**	—		37,530
CASI note - long term (see Note 11)	—		1,517
Other assets	$	10,158	$	53,783

* This value represents the non-current portion of the refundable alternative minimum tax credit that is expected to be received over the next few years (see Note 18).

** As of March 31, 2018, we reclassified our presentation of these equity securities from this account caption to “marketable securities” on our accompanying Consolidated Balance Sheets - (see Note 3(a)).

Schedule of Accounts Payable and Other Accrued Obligations

"Accounts payable and other accrued liabilities" consists of the following:

	December 31,
	2018		2017
Trade accounts payable and other accrued liabilities	$	44,919	$	33,648
Accrued rebates	8,371		7,990
Accrued product royalty	4,337		4,339
Allowance for returns	5,171		4,045
Accrued data and distribution fees	3,248		4,305
Accrued GPO administrative fees	296		296
Accrued inventory management fee	388		1,126
Allowance for chargebacks	2,730		2,368
Accounts payable and other accrued liabilities	$	69,460	$	58,117

Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

Description	Rebates and Chargebacks			Data and Distribution, GPO Fees, and Inventory Management Fees			Returns
Balance as of December 31, 2016	$	9,817		$	5,146		$	2,309
Add: provisions	106,647			20,104			2,807
(Less): credits or actual allowances	(106,106		)	(19,523		)	(1,071		)
Balance as of December 31, 2017	10,358			5,727			4,045
Add: provisions	65,751			13,962			1,700
(Less): credits or actual allowances	(65,008		)	(15,757		)	(574		)
Balance as of December 31, 2018	$	11,101		$	3,932		$	5,171

Deferred Revenue

Contract liabilities" consists of the following:

	December 31,
	2018		2017
Deposit made by licensee for EVOMELA supply in China territory	$	4,850	$	—
Contract liabilities	$	4,850	$	—

Deferred Revenue, by Arrangement, Disclosure

Deferred revenue (current and non-current) consists of the following:

	December 31,
	2018		2017
EVOMELA deferred revenue	$	—	$	3,819
ZEVALIN out-license in India territory (see Note 17(b)(iii))	—		368
Deferred revenue*	$	—	$	4,187

* On January 1, 2018, we reclassified the deferred revenue related to our EVOMELA product sales and our ZEVALIN out-license in the India territory of $3.8 million and $0.4 million, respectively. These amounts were included in the $4.7 million aggregate decrease to “accumulated deficit” on January 1, 2018, in accordance with the adoption of Topic 606 (see Note 2(i)).

Summary of Other Long-Term Liabilities

"Other long-term liabilities" consists of the following:

	December 31,
	2018		2017
Accrued executive deferred compensation	$	5,474	$	5,928
Deferred rent (non-current portion)	—		52
Clinical study holdback costs, non-current	—		59
Other tax liabilities	176		176
Other long-term liabilities	$	5,650	$	6,215